Charles River Laboratories Acquires K.F. and PathoQuest
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
The company states: "Charles River announced two planned acquisitions of K.F. (Cambodia) Ltd. and PathoQuest SAS; the addition of Dr. Namandje N. Bumpus as Chief Scientific and Innovation Officer; and is also providing an update on recent business trends and a preliminary 2026 outlook at the J.P. Morgan 44th Annual Healthcare Conference. Charles River Laboratories has signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a Cambodia-based provider of non-human primates (NHPs) for regulatory required biomedical, pharmaceutical, and toxicological research purposes. The total purchase price is expected to be approximately $510.0 million, subject to customary closing adjustments. The transaction is expected to close early in the first quarter of 2026. K.F. is not expected to generate meaningful third-party revenue going forward; however, the transaction is expected to be accretive to non-GAAP earnings per share by approximately $0.25 in 2026 and by approximately $0.60 in 2027. K.F. will become part of the Company's DSA segment for the purpose of being vertically integrated into its DSA supply operations. Items excluded from non-GAAP earnings per share are expected to include all acquisition-related costs, which primarily include amortization, third-party advisory fees, and certain integration costs. Charles River Laboratories has also exercised its option to acquire the remaining 79% equity stake that it does not already own of PathoQuest SAS, a Paris, France-based provider of industry-leading next generation sequencing (NGS) solutions for manufacturing quality-control testing for biopharmaceutical companies." James C. Foster, CEO, said, "As the biopharmaceutical industry evolves, we are committed to remaining a leader in regulatory required drug development solutions. We intend to accomplish this by pairing the best traditional testing methods to ensure patient safety with scientific advancements and innovative solutions to drive greater efficiency and success in our clients' drug development programs. Today's announcement of the planned acquisitions will help us accomplish these goals and invest in core areas of growth. The addition of K.F. will promote enhanced efforts to secure and safeguard our supply chain for traditional in vivo testing practices, while PathoQuest will further enable us to champion methodologies to reduce animal use, including through its in vitro, next-generation sequencing technologies. We are focused on continuing to lead the industry through advances in drug development, and the addition of Dr. Bumpus to drive our scientific innovation further supports this goal. We look forward to welcoming Dr. Bumpus, as well as the teams at PathoQuest and K.F., to help enhance our ability to serve our clients. We believe we are well positioned as we move into 2026 with a clear strategic direction, actions underway to unlock shareholder value, and are cautiously optimistic that the positive signs in the biopharmaceutical demand environment will continue this year. To support this view, we are pleased with the recent improvement in DSA demand trends during the second half of 2025, including a fourth-quarter increase in the net book-to-bill."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRL
Wall Street analysts forecast CRL stock price to rise
12 Analyst Rating
9 Buy
3 Hold
0 Sell
Strong Buy
Current: 158.860
Low
185.00
Averages
226.70
High
265.00
Current: 158.860
Low
185.00
Averages
226.70
High
265.00
About CRL
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cold Chain Monitoring Market Expands Rapidly
- Market Size Growth: According to Valuates Reports, the global cold chain monitoring market was valued at $7.414 billion in 2025 and is projected to reach $15.39 billion by 2032, with a CAGR of 11.2%, indicating strong market demand and investment potential.
- Technology-Driven Transformation: As the demand for compliance and quality increases, companies are transitioning from basic temperature logging systems to advanced connected monitoring solutions, which not only enhance transparency in transportation and storage but also improve management capabilities for temperature-sensitive products, reducing financial losses and compliance risks.
- Rising Hardware Demand: Cold chain monitoring relies on reliable sensors and data logging devices, with increasing market demand for these hardware components, particularly in the pharmaceutical and food sectors, ensuring the safety and quality of high-value shipments and driving continuous deployment of equipment.
- Last-Mile Challenges: Last-mile delivery has become a significant growth factor for the cold chain monitoring market, as monitoring systems assist logistics teams in tracking shipment conditions and triggering alerts, ensuring product quality is maintained until delivery to the final customer, meeting the growing demands of home healthcare and e-commerce.
See More
Charles River Laboratories Q1 2026 Results Exceed Expectations
- Strong Performance: Charles River Laboratories reported Q1 2026 sales of $995.8 million, reflecting a 1.2% year-on-year growth that surpassed analyst expectations of $977.4 million, indicating robust market performance.
- Profitability Improvement: The non-GAAP EPS of $2.06 exceeded analysts' forecast of $1.94 by 6%, showcasing the company's success in cost control and efficiency enhancements.
- Strategic Restructuring: The company completed the divestiture of its CDMO and Cell Solutions businesses and plans to sell certain European discovery sites, aiming to sharpen its focus on core drug development and testing capabilities to enhance future profitability.
- Technology Investments: Charles River is increasing investments in digital platforms and artificial intelligence, which are expected to accelerate scientific workflows and improve client experiences, driving future business growth.
See More
Charles River Labs Q1 Earnings Beat Estimates but Lowers FY2026 Forecast
- Earnings Beat: Charles River Laboratories exceeded Q1 earnings estimates, indicating strong performance in the biopharmaceutical services sector, although specific figures were not disclosed, this result boosts investor confidence.
- FY2026 Forecast Cut: The company lowered its FY2026 forecast, reflecting uncertainties in the future market environment, which may impact investor confidence in long-term growth.
- Analysts Maintain Positive Outlook: Despite the forecast cut, analysts remain optimistic about Charles River Labs, raising price targets, indicating strong market confidence in the company's future development.
- Positive Market Reaction: Investors reacted positively to the analysts' optimistic outlook, which may drive stock prices up in the short term, further solidifying the company's position in the biopharmaceutical services market.
See More
Charles River Laboratories Set to Announce Q1 Earnings on May 7
- Earnings Announcement: Charles River Laboratories is set to release its Q1 2023 earnings report on May 7 before market open, with consensus EPS estimate at $1.94, reflecting a 17.1% year-over-year decline, and revenue estimate at $977.44 million, down 0.7% year-over-year, indicating potential performance challenges.
- Historical Performance: Over the past two years, CRL has consistently beaten both EPS and revenue estimates 100% of the time, showcasing its financial stability and market confidence, although recent downward revisions in EPS and revenue forecasts suggest emerging concerns.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates, with 8 downward adjustments, while revenue estimates also saw no upward revisions and 6 downward adjustments, reflecting a cautious market outlook on the company's future growth.
- Market Sentiment: Despite disruptions related to NAMs, RBC has assigned an
See More
Charles River Laboratories to Release Q1 2026 Financial Results
- Earnings Release Schedule: Charles River Laboratories is set to announce its Q1 2026 financial results on May 7, 2026, before the market opens, reflecting its ongoing performance and growth in the biopharmaceutical sector.
- Conference Call Details: A conference call will be held on the same day at 8:30 AM ET to discuss the financial results, allowing investors to engage and enhancing transparency and communication.
- Live Webcast and Replay: Investors will have the opportunity to listen to a live webcast of the conference call through the company's website, with a replay also available, ensuring broad dissemination and access to information.
- Company Overview: Charles River Laboratories provides essential products and services to pharmaceutical, biotechnology companies, and academic institutions globally, focusing on accelerating research and drug development to improve the discovery and safe manufacture of new therapies.
See More
RBC Capital Markets Initiates Outperform Rating on CRL Amid NAMs Disruption
- Coverage Initiation: RBC Capital Markets has initiated coverage on Charles River Laboratories (CRL) with an Outperform rating, highlighting that the company remains attractively valued despite disruptions from New Alternative Methods (NAMs) in preclinical research.
- Market Risk Assessment: Analyst Ryan Halsted noted that the use of NAMs is growing at approximately 38% annually, and with the FDA easing animal testing requirements, this poses a headwind for CRL, although the market may be overpricing this risk.
- Future Growth Expectations: Preclinical R&D is expected to accelerate into 2027, positioning CRL, as a leading contract research organization, to benefit significantly, with analysts projecting high-single-digit revenue growth in line with its long-term targets of 6%-8%.
- Price Target Setting: The RBC analyst set a price target of $215 per share for CRL, reflecting an optimistic outlook on the company's future performance, particularly in light of the impending patent cliff.
See More
Cold Chain Monitoring Market Expands Rapidly
- Market Size Growth: According to Valuates Reports, the global cold chain monitoring market was valued at $7.414 billion in 2025 and is projected to reach $15.39 billion by 2032, with a CAGR of 11.2%, indicating strong market demand and investment potential.
- Technology-Driven Transformation: As the demand for compliance and quality increases, companies are transitioning from basic temperature logging systems to advanced connected monitoring solutions, which not only enhance transparency in transportation and storage but also improve management capabilities for temperature-sensitive products, reducing financial losses and compliance risks.
- Rising Hardware Demand: Cold chain monitoring relies on reliable sensors and data logging devices, with increasing market demand for these hardware components, particularly in the pharmaceutical and food sectors, ensuring the safety and quality of high-value shipments and driving continuous deployment of equipment.
- Last-Mile Challenges: Last-mile delivery has become a significant growth factor for the cold chain monitoring market, as monitoring systems assist logistics teams in tracking shipment conditions and triggering alerts, ensuring product quality is maintained until delivery to the final customer, meeting the growing demands of home healthcare and e-commerce.
See More
Charles River Laboratories Q1 2026 Results Exceed Expectations
- Strong Performance: Charles River Laboratories reported Q1 2026 sales of $995.8 million, reflecting a 1.2% year-on-year growth that surpassed analyst expectations of $977.4 million, indicating robust market performance.
- Profitability Improvement: The non-GAAP EPS of $2.06 exceeded analysts' forecast of $1.94 by 6%, showcasing the company's success in cost control and efficiency enhancements.
- Strategic Restructuring: The company completed the divestiture of its CDMO and Cell Solutions businesses and plans to sell certain European discovery sites, aiming to sharpen its focus on core drug development and testing capabilities to enhance future profitability.
- Technology Investments: Charles River is increasing investments in digital platforms and artificial intelligence, which are expected to accelerate scientific workflows and improve client experiences, driving future business growth.
See More
Charles River Labs Q1 Earnings Beat Estimates but Lowers FY2026 Forecast
- Earnings Beat: Charles River Laboratories exceeded Q1 earnings estimates, indicating strong performance in the biopharmaceutical services sector, although specific figures were not disclosed, this result boosts investor confidence.
- FY2026 Forecast Cut: The company lowered its FY2026 forecast, reflecting uncertainties in the future market environment, which may impact investor confidence in long-term growth.
- Analysts Maintain Positive Outlook: Despite the forecast cut, analysts remain optimistic about Charles River Labs, raising price targets, indicating strong market confidence in the company's future development.
- Positive Market Reaction: Investors reacted positively to the analysts' optimistic outlook, which may drive stock prices up in the short term, further solidifying the company's position in the biopharmaceutical services market.
See More
Charles River Laboratories Set to Announce Q1 Earnings on May 7
- Earnings Announcement: Charles River Laboratories is set to release its Q1 2023 earnings report on May 7 before market open, with consensus EPS estimate at $1.94, reflecting a 17.1% year-over-year decline, and revenue estimate at $977.44 million, down 0.7% year-over-year, indicating potential performance challenges.
- Historical Performance: Over the past two years, CRL has consistently beaten both EPS and revenue estimates 100% of the time, showcasing its financial stability and market confidence, although recent downward revisions in EPS and revenue forecasts suggest emerging concerns.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates, with 8 downward adjustments, while revenue estimates also saw no upward revisions and 6 downward adjustments, reflecting a cautious market outlook on the company's future growth.
- Market Sentiment: Despite disruptions related to NAMs, RBC has assigned an
See More
Charles River Laboratories to Release Q1 2026 Financial Results
- Earnings Release Schedule: Charles River Laboratories is set to announce its Q1 2026 financial results on May 7, 2026, before the market opens, reflecting its ongoing performance and growth in the biopharmaceutical sector.
- Conference Call Details: A conference call will be held on the same day at 8:30 AM ET to discuss the financial results, allowing investors to engage and enhancing transparency and communication.
- Live Webcast and Replay: Investors will have the opportunity to listen to a live webcast of the conference call through the company's website, with a replay also available, ensuring broad dissemination and access to information.
- Company Overview: Charles River Laboratories provides essential products and services to pharmaceutical, biotechnology companies, and academic institutions globally, focusing on accelerating research and drug development to improve the discovery and safe manufacture of new therapies.
See More
RBC Capital Markets Initiates Outperform Rating on CRL Amid NAMs Disruption
- Coverage Initiation: RBC Capital Markets has initiated coverage on Charles River Laboratories (CRL) with an Outperform rating, highlighting that the company remains attractively valued despite disruptions from New Alternative Methods (NAMs) in preclinical research.
- Market Risk Assessment: Analyst Ryan Halsted noted that the use of NAMs is growing at approximately 38% annually, and with the FDA easing animal testing requirements, this poses a headwind for CRL, although the market may be overpricing this risk.
- Future Growth Expectations: Preclinical R&D is expected to accelerate into 2027, positioning CRL, as a leading contract research organization, to benefit significantly, with analysts projecting high-single-digit revenue growth in line with its long-term targets of 6%-8%.
- Price Target Setting: The RBC analyst set a price target of $215 per share for CRL, reflecting an optimistic outlook on the company's future performance, particularly in light of the impending patent cliff.
See More
